Skip to main content
Friday 3 April 2026
BlueSky linkedin youtube
header links
  • Get Newsletters
  • Media Kit
Home
Pharmaphorum menu first category
  • News
  • Views & Analysis
  • Deep Dive
    • Equity and Sustainability
    • Research & Development
    • Market Access
    • Oncology
    • Artificial Intelligence
    • Patients & Partnerships
    • GLP-1
    • Previous Editions
  • Webinars
  • Podcasts
  • Videos
  • Spotlight on
    • ASCO
    • BIO-Europe
    • C-Suite Innovators
    • ESMO
    • Frontiers Health
    • JP Morgan
    • Global Policy Insights
  • Events
Pharmaphorum
close
    SECTION
    • News
    • Views & Analysis
    • Deep Dive
      • Research & Development
      • Market Access
      • Oncology
      • Artificial Intelligence
      • Patients & Partnerships
      • Commercialisation
      • Previous Editions
    • Webinars
    • Podcasts
    • Videos
    • White Papers
    • Events
Channels
    Channels
    • Sales & Marketing
    • R&D
    • Digital
    • Market Access
    • Oncology
    • Patients
    • Spotlight On
Channels
  • Sales & Marketing
  • R&D
  • Digital
  • Market Access
  • Oncology
  • Patients
  • Spotlight On
    SUB NAVIGATION
    • Live Coverage
    • Partner Content
    • About us
    • Work for us
    • Contribute
    • Contact us
    • Advertise

Newsletters and Deep Dive digital magazine

 
 
Sign up
youtube linkedin BlueSky
Sign in

News

News
California Governor Gavin Newsom

California is first US state to ban pay-for-delay deals

News
Gilead_yescarta_production

Scotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphoma

News
Clinatec _ Juliette Treillet-32

Mind-controlled exoskeleton suit allows paralysed man to wal...

News
drugs-1276787_1920

J&J settles Ohio lawsuits for $20m as opioid litigation trai...

Johnson & Johnson has managed to put opioid litigation in Ohio behind it with a $20 million settlement, saying that will

News
Aimovig

Blow to Novartis as NICE rejects migraine drug Aimovig again

News
Corbyn at Labour conference

Labour government would use compulsory licensing for expensi...

  • Load more results

Editor's Picks

  1. Novartis snaps up PI3Kα breast cancer drug in $3bn deal
  2. US court says pharma giants must face False Claims suit
  3. Meningitis outbreak in UK prompts call to widen vaccination
  4. US judge rules Kennedy's vaccine changes 'unlawful'
  5. Generic semaglutide in India, and other weight-loss news
News
Ambrosia's sweet $100m round, and other biofinancings

Ambrosia's sweet $100m round, and other biofinancings

Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png
Sales & Marketing
Using AI-driven synthetic personas to take your insights further
Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Pharmaphorum Menu
  • Digital
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Market Access
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Oncology
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Patients
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • R&D
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Sales & Marketing
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Spotlight on
    • Axtria Ignite 2025
    • Frontiers Health 2024
    • Life Science Industry Report
    • World Without Disease Summit

Sign up for email newsletters and Deep Dive

Get Newsletters

 
 
youtube linkedin BlueSky
Pharmaphorum
About us Advertising Contact us
Contribute Cookie Policy Privacy Policy
Terms & Conditions Work for us
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company